WO1998053876A1 - Electrically activated substance and method for making the same - Google Patents
Electrically activated substance and method for making the same Download PDFInfo
- Publication number
- WO1998053876A1 WO1998053876A1 PCT/US1998/010446 US9810446W WO9853876A1 WO 1998053876 A1 WO1998053876 A1 WO 1998053876A1 US 9810446 W US9810446 W US 9810446W WO 9853876 A1 WO9853876 A1 WO 9853876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- current
- conducting fluid
- alternating current
- recited
- current conducting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present invention relates generally to cosmetic/ medical therapy and more particularly to an electrically activated substance for use in such therapy.
- Transcutaneous electrotherapy involves the passage of an electrical current from one electrode to another, such that the therapeutic current is caused to pass directly through a target tissue of the patient.
- Exemplary devices used in the performance of transcutaneous electrotherapy are provided in United States Patent Nos . 397,474; 3,794,022; 4,180,079; 4,446,870; 5,058,605; in French Patent 2621-827- A; and European Patent Application EP-377-057-A.
- transcutaneous electrotherapy Although the use of transcutaneous electrotherapy has proven beneficial, such contemporary cosmetic/medical therapy suffers from inherent disadvantages. For example, during transcutaneous electrotherapy electrical current passes through the target tissue of the patient. Many patients may find this painful or otherwise undesirable. Further, transcutaneous electrotherapy is generally not self-administrable, and therefore generally requires the presence of a skilled operator. The administration of transcutaneous electrotherapy also tends to be costly.
- the present invention specifically addresses and alleviates the above-mentioned deficiencies associated with the prior art. More particularly, the present invention comprises a method for providing cosmetic/medical therapy, the method comprising the steps of electrically activating a substance and administering the electrically activated substance to a subject. Administering the electrically activated substance to the subject provides a cosmetic/medical benefit to the subject.
- the subject as described herein is a human being, those skilled in the art will appreciate that the methodology of the present invention may be practiced upon various different animals. Thus, the use of a human being in this application is by way of example only and not by way of limitation.
- the electrically activated substance is applied topically to treat skin problems such as wrinkles, cuts, abrasions, etc.
- the electrically activated substance may also be ingested, so as to treat internal medical conditions, where indicated.
- the electrically activated substance comprises water, preferably distilled water.
- water preferably distilled water.
- various other substances particularly those comprised of simple molecules, may likewise be utilized.
- the step of electrically activating the substance comprises applying an electrical signal to the substance.
- an alternating current signal preferably having a generally symmetric waveform.
- a sinusoidal waveform, a square waveform, and a triangular waveform are suitable.
- Those skilled in the art will appreciate that various other generally symmetric waveforms are likewise suitable.
- the electrical signal preferably comprises an alternating current signal having a frequency of between approximately 5 or 10 KHz and approximately 1 MHz, preferably between approximately 50 KHz and approximately 100 KHz. According to the preferred embodiment of the present invention, the frequency of the electrical signal is varied within a frequency range of approximately 50 KHz to 100 KHz.
- the alternating current has approximately zero direct current bias.
- the electrical signal is preferably applied to the substance via a capacitor-resistor network.
- the electrical signal is applied to the substance via an isolation transformer.
- the electrical signal preferably has a voltage of between approximately 50 volts rms and approximately 150 volts rms.
- the electrical signal is applied to the substance to be electrically activated via at least one pair of electrodes.
- a plurality of pairs of electrodes may be utilized, if desired.
- the electrodes are preferably comprised of either a biologically inert, non-reactive metal or a non-metallic material having a low atomic number. For example, it has been found that gold, carbon 12, and graphite-carbon loaded thermo-plastic material are suitable.
- distilled water When distilled water is to be electrically activated, then a substance is added to the water to form an electrolyte therefrom, so as to facilitate current flow therethrough.
- sodium chloride (table salt) is utilized to form an electrolyte from distilled water.
- tap water is typically suitable and does not generally require the addition of any other substance thereto.
- the substance e.g., sodium chloride
- the substance is added to the distilled water while monitoring current flow therethrough, until the desired current is obtained.
- approximately 1 amp rms of current is caused to flow through the substance being electrically activated.
- a voltage of approximately 100 volts rms is required to effect a current of 1 amp rms. It has been found that currents as low as 1 milliamp may be used, if desired.
- the electrodes preferably have a resistance below 500 ohms per square centimeter, preferably below 50 ohms per square centimeter.
- the electrically activated substance When administered topically, approximately 0.05 ml of the electrically activated substance is applied per square centimeter of treatment area.
- the electrically activated substance is preferably administered 3 to 6 times with approximately 1 to 4 days between administrations.
- Such topical application of the electrically activated substance of the present invention has been found to be effective in mitigating wrinkles on human skin.
- Figure 1 is a perspective view showing a variable frequency current source being utilized to electrically charge a liquid contained within a beaker;
- Figure 2 is a block diagram showing a first alternative configuration of the apparatus of Figure 1;
- Figure 3 is a block diagram showing a second alternative configuration of the apparatus of Figure 1; and Figure 4 is a flow chart showing the steps involved in the practice of the method for forming an electrically charged substance, according to the present invention.
- a variable frequency current source 10 is electrically connected, via wires 12 to probes or electrodes 14 which are at least partially immersed within the substance 18 to be electrically activated, which is contained within beaker 16.
- the variable frequency current source 10 preferably comprises the variable frequency current source having an output frequency range from approximately 10 KHz to approximately 1 MHz, having a voltage output from approximately 50 volts rms to 150 volts rms, and having a maximum current output in excess of 1 amp rms .
- variable frequency current source 10 provides an alternating current output having substantially 0 direct current bias.
- variable frequency current source 10 is capable of providing a generally symmetric waveform, such as a sinusoidal waveform, a square waveform, and/or a triangular waveform. As those skilled in the art will appreciate, various other generally symmetrical alternating current waveforms are likewise suitable.
- the frequency output of the variable frequency current source 10 is capable of being swept or automatically varied between a minimum and maximum frequency.
- the variable frequency current source 10 is capable of being manually swept in frequency.
- the wires 12 preferably comprise copper wires having a current rating sufficient to carry the required current, e.g., 1 amp rms, without excessive heating.
- Each electrode 14 is preferably comprised of a chemically and biologically inert material, preferably a non-reactive metal such as gold, or alternatively, a non- metal having a low atomic number. It is believed that it is not desirable to have ions form from the substance of the electrodes. For example, if lead electrodes are utilized, it has been found that lead ions permeate the substance being electrically activated, potentially resulting in undesirable contamination of the medium and potential poisoning of the patient to whom the electrically activated substance is administered. Although aluminum and copper electrodes may be suitable in some applications, they are generally thought to be undesirable. Carbon 12 has been found to be suitable for the construction of electrodes according to the present invention. More particularly, carbon electrodes may be formed utilizing contemporary plastic injection molding techniques wherein a graphite-carbon loaded thermo-plastic material, such as nylon, is injected into the molds.
- a graphite-carbon loaded thermo-plastic material such as nylon
- Typical dimensions for the electrodes 14 are 3 mm thick, 20 mm wide, and 10 cm long. However, as those skilled in the art will appreciate, various different dimensions and cross-sectional configurations, e.g., round, oval, square, triangular, etc., may likewise be suitable.
- the electrical resistance of the finished electrodes is preferably less than 500 ohms/cm 2 , preferably less than 50 ohms/cm 2 .
- the two electrodes are positioned several centimeters apart in a 250 ml container, e.g., a beaker.
- the container is formed of a non-metallic material, such as glass.
- the method for electrically activating a substance is preferably practiced utilizing approximately 200 ml of the substance at a time.
- the quantity of substance electrically activated may be varied by varying the dimensions of the container, electrodes, and by varying the strength of the electrical signal appropriately.
- current flow through the substance being electrically activated 18 is monitored as an electrolytic substance is added thereto so as to form an electrolyte .
- an electrolytic substance for example, sodium chloride is added to the water, so as to form an electrolyte.
- sodium chloride is added to the water, so as to form an electrolyte.
- current flow through the water is monitored until the desired current flow is achieved, thereby indicating that sufficient sodium chloride has been added to the water.
- approximately 1 amp rms of current is caused to flow through the substance being electrically activated while a voltage of approximately 100 volts rms is applied thereto.
- a voltage of approximately 100 volts rms is applied thereto.
- the electrically activated substance is typically active for only a limited amount of time after current flow therethrough has ceased.
- the electrically activated substance is thought to be most effective if utilized within approximately 4 hours after its production.
- the electrically activated substance is thought to be somewhat effective for up to 4 days after its production. It is believed that the decay in the effectiveness of the electrically activated substance is logarithmic in nature, with more than half of the eff ctiveness thereof lost within approximately 24 hours.
- the specified values for the applied voltage, duration, and conductivity of the medium may be varied, as desired. Indeed, a reduction in the effectiveness of the electrically activated substance may be compensated for by varying one or the other of the production parameters.
- a lower voltage may be utilized if additional sodium chloride is added to the solution. However, if too much sodium chloride is added, then the solution may become less bio-compatible. Conversely, if less sodium chloride is utilized, then a higher voltage is necessary to obtain sufficient current flow through the substance. Inadequate current flow through the substance results in substantially reduced effectiveness of the electrically activated substance .
- the electrically activated substance of the present invention provides beneficial cosmetic/medical effects by stimulating the well known current of injury commonly associated with tissue trauma.
- tissue when tissue is injured, a small electric current is generated.
- This current is a result of a voltage producing charge imbalance which occurs when portions of previously connected tissue are disconnected from one another, such as occurs if a bone is broken or skin is torn.
- This voltage causes a small amount of current, e.g., electrons or ions, to flow from one point to another within the tissue. Further disclosure of this effect can be found in The Body Electric, by Robert Becker, M.D., among others.
- blastema are a collection of primitive, unformed cells, which gather at an entry site and later developed into replacement tissue.
- the electrically activated substance of the present invention effects in biological tissue a disruptive electrical imbalance, similar to that which occurs when a mechanical strain to the tissue has occurred. This electrical imbalance then triggers accelerated metabolic activity in the treatment area. Blood flow accelerates while cellular metabolic activity and interactions increase. Capillaries dilate and there is increased activity toward restored homeostasis. In this process, toxins, free radicals, metabolic waste products, and unused remnant material may be re-formed or flushed away.
- the electrically activated substance of the present invention should not be applied to fresh injury sites, since it may interfere with the timing and development of the natural current of injury, thereby inhibiting the healing process. However, once the injury has stabilized, the electrically activated substance of the present invention may be applied thereto so as to enhance or re-activate the healing process.
- One exemplary use of the electrically activated substance of the present invention is the removal of skin wrinkles .
- facial wrinkles may be treated with electrically activated water.
- the water is activated with a frequency of between approximately 50 KHz and 100 KHz. It has been found that such electrically activated water is particularly beneficial to the skin and other soft tissue.
- Such electrically activated water is preferably spritzed or dabbed onto the skin for topical application thereto.
- the typical dose rate is approximately 0.05 ml/cm 2 of treatment area. Mitigation of skin wrinkles typically occurs beginning within approximately 30 minutes, with the results being clearly visible .
- Blood flow and metabolic activity accelerates and has been found to peak within approximately 45 minutes after the application of the electrically activated substance o the present invention. After this period of increased blood flow and accelerated metabolism, the skin and tissue enters a recovery phase wherein the cellular structure thereof is rebuilt. Skin begins to draw together, getting tighter, thicker, and causing wrinkles to shrink. Additional collagen forms at the site of treatment.
- This recovery phase typically has a duration of approximately 1 to 4 days. After 4 days, approximately all such recovery has occurred. At the end of the recovery phase, another treatment may be applied. It has been found that the recovery phase must be complete before a subsequent treatment, so as to avoid overwhelming the response mechanism.
- the dose rate is preferably comparatively small, approximately 2 ml per day for 6 weeks. It is thought that such therapy is particularly beneficial for heart and circulatory problems.
- this technique has been also found at least partially effective in the conversion of surgical scar tissue from a typically necrid white fibrous collagen material back into normal healthy pink skin with nerve sensitivity, blood vessels, and even hair follicles. These results may be obtained with administration of a daily to semi-daily topical application, typically over a 6 month period. As the collagen is initially resistant to absorbing the medium, a vasodilator additive is effective in speeding results by increasing penetration of the medium.
- the electrically activated substance of the present invention functions as a transfer agent or medium, at no time is there any current flow from the variable frequency current source through biological tissue. Thus, there is no chance of burns, thereby enhancing the safety of such treatment. Further, there is no muscle contraction or nerve impulse firing as a result of using the electrically activated substance of the present invention, as is common during contemporary transcutaneous electrotherapy .
- variable frequency current source 10 does not provide approximately 0 direct current bias, then the output thereof can be processed so as to mitigate direct current bias.
- a resistor- capacitor network 22 filters the output of the variable frequency current source 10, so as to mitigate direct current bias.
- a resistor-capacitor network comprises at least one capacitor in series with the substance being electrically activated and at least one resistor in parallel therewith.
- the resistor-capacitor network 22 functions according to well known principles to mitigate the presence of DC bias in the substance being electrically charged.
- filters may be utilized.
- a capacitor inductor network may be utilized.
- an isolation transformer 24 isolates the substance 18 to be electrically charged from direct current bias present in the output of the variable frequency current source 10.
- variable frequency current source 10 does not include a means for monitoring current flow through the substance 18 being electrically activated
- such means is preferably included in the electrical path of the electrodes 14.
- an amp meter 20 may be inserted in line or applied inductively to one of the wires 12 which provide an electrical pathway for the current which travels between the electrodes 14.
- an oscilloscope may be utilized to monitor current flow between the electrodes 14.
- the method for forming an electrically activated substance of the present invention generally comprises providing distilled water 30, adding sodium chloride to the distilled water while monitoring current flow between the electrodes 32, applying alternating current to the electrodes 34, and, administering the electrically activated substance 36, preferably within four hours after the electrical activation thereof.
- the electrically activated substance is only administered after first discontinuing the application of current thereto. In this manner, the electric current can be applied to an intermediate material, (i.e., the electrically activated substance) , rather than directly to a person.
- an intermediate material i.e., the electrically activated substance
- a substantial amount of power may be applied to the electrically activated substance rather than directly to a person.
- much more power e.g., approximately 100 watts
- the minimum amount of power applied to the substance during electrical activation thereof must be sufficient to overcome the activation decay rate of the substance.
- the more electrical power applied to the substance the slower the rate at which the electrically activated substance's effectiveness decays. It has been found that the application of approximately 100 watts of electrical power to water results in an acceptable decay rate, as discussed in detail above.
- Non-distilled or tap water or other bio-compatible compounds, including tissue may be utilized instead of distilled water. It has been found that tap water is frequently suitable for use in the practice of the present invention. However, as those skilled in the art will appreciate, the types and amounts of impurities found in tap water vary considerably from one location to another. Thus, if an accurate analysis of the tap water to be utilized is not available, then the effectiveness thereof must be determined by trial and error. Those skilled in the art will appreciate that various other electrolyte forming substances, other than sodium chloride are likewise suitable.
- alternating current 34 to the substance to be electrically charged preferably takes place for a duration of approximately 4 to 8 hours. When small gas bubbles appear on the electrodes, then the current has been applied for a sufficient length of time.
- the electrically activated substance is created using the power levels, frequencies, current densities, and dosage quantities described herein, or parameters similar to those described herein. When the substance is produced in this manner, it takes on unique properties (possibly on an atomic level) , which make it particularly well suited for the practice of the present invention. It is understood that the exemplary electrically activated substance and method for making the same described herein and shown in the drawings represents only a presently preferred embodiment of the invention. Indeed, various modifications and additions may be made to such embodiment without departing from the spirit and scope of the invention. For example, various different sizes, shapes, and configurations of the container, the electrodes, and the source of alternating current are contemplated.
- electrically activated substance is by way of example only, not by way of limitation. Indeed, it is also anticipated that gases, as well as liquids, may be electrically activated according to the present invention. Electrically activated gases may find particular application in the treatment of pulmonary disorders .
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9815511-3A BR9815511A (en) | 1997-05-29 | 1998-05-22 | Process for preparing and using a substance |
JP50077099A JP2002502392A (en) | 1997-05-29 | 1998-05-22 | Electrically activated substance and method for producing the same |
AU75886/98A AU728564B2 (en) | 1997-05-29 | 1998-05-22 | Electrically activated substance and method for making the same |
EP98923647A EP1027098A4 (en) | 1997-05-29 | 1998-05-22 | Electrically activated substance and method for making the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/865,253 | 1997-05-29 | ||
US08/865,253 US5885241A (en) | 1997-05-29 | 1997-05-29 | Treatment with an electrically-activated substance |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998053876A1 true WO1998053876A1 (en) | 1998-12-03 |
Family
ID=25345052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/010446 WO1998053876A1 (en) | 1997-05-29 | 1998-05-22 | Electrically activated substance and method for making the same |
Country Status (6)
Country | Link |
---|---|
US (3) | US5885241A (en) |
EP (1) | EP1027098A4 (en) |
JP (1) | JP2002502392A (en) |
AU (1) | AU728564B2 (en) |
BR (1) | BR9815511A (en) |
WO (1) | WO1998053876A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061221A1 (en) * | 1999-04-09 | 2000-10-19 | Orton Kevin R | Method of providing cosmetic/medical therapy |
WO2003080176A2 (en) * | 2002-03-21 | 2003-10-02 | Orton Kevin R | Preparation and delivery of healthcare services utilizing electrolytic medicaments |
US6920884B2 (en) | 1997-05-29 | 2005-07-26 | Kevin Orton | Method of providing cosmetic/medical therapy |
FR2968563A1 (en) * | 2010-12-08 | 2012-06-15 | Ilinx | Dermatological composition based on vegetable oil, having specific electrical potential, useful e.g. for the treatment of a neurological disorder, obesity, neuroendocrine disorder and pain |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5885241A (en) * | 1997-05-29 | 1999-03-23 | Orton; Kevin R. | Treatment with an electrically-activated substance |
WO2000007658A1 (en) * | 1998-08-06 | 2000-02-17 | Shmuel Peltz | Method and appliances for electrostimulation |
EP1666018A1 (en) * | 1999-09-21 | 2006-06-07 | Kevin R. Orton | Container for electrically preparing injectable substances |
DE60031701T2 (en) * | 1999-09-21 | 2007-09-06 | Kevin R. San Clemente Orton | Apparatus for the electrical preparation of injectable substances |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US397474A (en) | 1889-02-05 | Therapeutical electrode | ||
US408607A (en) * | 1889-08-06 | Electric drinking-vessel | ||
US882378A (en) * | 1907-01-23 | 1908-03-17 | Emanuel Friendlich | Drinking vessel. |
US1108686A (en) * | 1912-08-03 | 1914-08-25 | Harry Bonis | Electrotherapeutic fluid electrode. |
US2801634A (en) * | 1954-05-12 | 1957-08-06 | Cyr William H De St | Muscle stimulating method and apparatus |
US3794022A (en) | 1972-06-30 | 1974-02-26 | E Nawracaj | Dual oscillator, variable pulse duration electrotherapeutic device |
US4180079A (en) | 1978-03-16 | 1979-12-25 | Wing Thomas W | Electroacupuncture instrument |
US4446870A (en) | 1978-03-16 | 1984-05-08 | Wing Thomas W | Electrical treatment method |
FR2621827A1 (en) | 1987-10-20 | 1989-04-21 | Bernardini Franco | Portable stimulator for electroanalgesia with transcutaneous effect |
EP0377057A1 (en) | 1988-12-30 | 1990-07-11 | Leandro Bernardini | Hand-operated electromedical device for analgesic skin treatments |
US5058605A (en) | 1989-02-22 | 1991-10-22 | Ceske Vysoke Uceni Technicke | Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR936475A (en) * | 1947-07-30 | 1948-07-21 | Treatment of all products by multiplied electric waves of short and very short lengths and very high frequencies | |
US3163166A (en) * | 1961-04-28 | 1964-12-29 | Colgate Palmolive Co | Iontophoresis apparatus |
US4305390A (en) * | 1975-11-28 | 1981-12-15 | Massachusetts Institute Of Technology | Method for generating oxygen in an excited electronic state and inactivation of microorganisms |
CA1140076A (en) * | 1977-04-07 | 1983-01-25 | Franco Donadelli | Solution of tissue-regenerating extracts treated electrolytically and with alternating electric field |
IT1132508B (en) * | 1980-07-04 | 1986-07-02 | Franco Donadelli | METHOD FOR INCREASING METABOLIC PROCESSES OF EPITELS BY BIOCHEMICAL APPLICATION OF AN ELECTRIC FIELD |
HU185691B (en) * | 1982-02-09 | 1985-03-28 | Richter Gedeon Vegyeszet | Process for preparing a new analgetic pharmaceutical composition |
US4572194A (en) * | 1982-10-05 | 1986-02-25 | Head Edwin L | Device for therapy of the human or animal body |
IT206759Z2 (en) * | 1985-07-08 | 1987-10-01 | Indiba Sa | ELECTRONIC DEVICE FOR COSMETIC MEDICAL THERAPY. |
AU6549486A (en) * | 1985-10-29 | 1987-05-19 | George William Sweeney Jr. | Method for accelerating growth rates |
JP2810665B2 (en) * | 1987-06-15 | 1998-10-15 | 松下電工株式会社 | Blood circulation promotion device |
AU4058789A (en) * | 1988-08-29 | 1990-03-23 | Moisey Dobruskin | Medicinal drug, method of treatment of human diseases therewith, and method and device for producing and preserving thereof |
US4980038A (en) * | 1988-10-17 | 1990-12-25 | Shizuho Watanabe | Cosmetic and method for production thereof |
US5012816A (en) * | 1989-08-31 | 1991-05-07 | Gabor Lederer | Electronic acupuncture device |
US5188738A (en) | 1990-08-06 | 1993-02-23 | Steven Kaali | Alternating current supplied electrically conductive method and system for treatment of blood and/or other body fluids and/or synthetic fluids with electric forces |
US5697882A (en) * | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US5350415A (en) * | 1993-03-08 | 1994-09-27 | Jozef Cywinski | Device for trophic stimulation of muscles |
IES58223B2 (en) * | 1993-03-22 | 1993-08-11 | Maitreya Corp Ltd | A homeopathic medicine |
ITPD940149A1 (en) | 1994-08-30 | 1996-03-01 | Silvano Marcolongo | HYDROS-ELECTROLYTIC PLATE GENERATING ACTIVE IONS. |
US5885241A (en) * | 1997-05-29 | 1999-03-23 | Orton; Kevin R. | Treatment with an electrically-activated substance |
-
1997
- 1997-05-29 US US08/865,253 patent/US5885241A/en not_active Expired - Lifetime
-
1998
- 1998-05-22 JP JP50077099A patent/JP2002502392A/en active Pending
- 1998-05-22 WO PCT/US1998/010446 patent/WO1998053876A1/en active IP Right Grant
- 1998-05-22 EP EP98923647A patent/EP1027098A4/en not_active Withdrawn
- 1998-05-22 BR BR9815511-3A patent/BR9815511A/en not_active Application Discontinuation
- 1998-05-22 AU AU75886/98A patent/AU728564B2/en not_active Ceased
-
1999
- 1999-02-26 US US09/259,120 patent/US6181962B1/en not_active Expired - Lifetime
-
2002
- 2002-07-26 US US10/207,651 patent/US20030120196A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US397474A (en) | 1889-02-05 | Therapeutical electrode | ||
US408607A (en) * | 1889-08-06 | Electric drinking-vessel | ||
US882378A (en) * | 1907-01-23 | 1908-03-17 | Emanuel Friendlich | Drinking vessel. |
US1108686A (en) * | 1912-08-03 | 1914-08-25 | Harry Bonis | Electrotherapeutic fluid electrode. |
US2801634A (en) * | 1954-05-12 | 1957-08-06 | Cyr William H De St | Muscle stimulating method and apparatus |
US3794022A (en) | 1972-06-30 | 1974-02-26 | E Nawracaj | Dual oscillator, variable pulse duration electrotherapeutic device |
US4180079A (en) | 1978-03-16 | 1979-12-25 | Wing Thomas W | Electroacupuncture instrument |
US4446870A (en) | 1978-03-16 | 1984-05-08 | Wing Thomas W | Electrical treatment method |
FR2621827A1 (en) | 1987-10-20 | 1989-04-21 | Bernardini Franco | Portable stimulator for electroanalgesia with transcutaneous effect |
EP0377057A1 (en) | 1988-12-30 | 1990-07-11 | Leandro Bernardini | Hand-operated electromedical device for analgesic skin treatments |
US5058605A (en) | 1989-02-22 | 1991-10-22 | Ceske Vysoke Uceni Technicke | Method and device for the controlled local, non-invasive application of dc pulses to human and animal tissues |
Non-Patent Citations (1)
Title |
---|
See also references of EP1027098A4 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6920884B2 (en) | 1997-05-29 | 2005-07-26 | Kevin Orton | Method of providing cosmetic/medical therapy |
WO2000061221A1 (en) * | 1999-04-09 | 2000-10-19 | Orton Kevin R | Method of providing cosmetic/medical therapy |
JP2002541222A (en) * | 1999-04-09 | 2002-12-03 | ケヴィン、 アール. オートン、 | How to perform cosmetic surgery / treatment |
AU777730B2 (en) * | 1999-04-09 | 2004-10-28 | Kevin R. Orton | Method of providing cosmetic/medical therapy |
KR100670096B1 (en) * | 1999-04-09 | 2007-01-17 | 오르톤 케빈 알 | Electrically activated substance for Internal medicament |
WO2003080176A2 (en) * | 2002-03-21 | 2003-10-02 | Orton Kevin R | Preparation and delivery of healthcare services utilizing electrolytic medicaments |
WO2003080176A3 (en) * | 2002-03-21 | 2004-02-12 | Kevin R Orton | Preparation and delivery of healthcare services utilizing electrolytic medicaments |
FR2968563A1 (en) * | 2010-12-08 | 2012-06-15 | Ilinx | Dermatological composition based on vegetable oil, having specific electrical potential, useful e.g. for the treatment of a neurological disorder, obesity, neuroendocrine disorder and pain |
Also Published As
Publication number | Publication date |
---|---|
AU728564B2 (en) | 2001-01-11 |
BR9815511A (en) | 2000-11-21 |
JP2002502392A (en) | 2002-01-22 |
AU7588698A (en) | 1998-12-30 |
US20030120196A1 (en) | 2003-06-26 |
US5885241A (en) | 1999-03-23 |
EP1027098A4 (en) | 2001-03-28 |
US6181962B1 (en) | 2001-01-30 |
EP1027098A1 (en) | 2000-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050217682A1 (en) | Method of providing cosmetic/medical therapy | |
GB2244654A (en) | Apparatus and method for transcranial electrotherapy | |
Konikoff | Electrical promotion of soft tissue repairs | |
US5885241A (en) | Treatment with an electrically-activated substance | |
US6488032B1 (en) | Method of providing cosmetic/medical therapy | |
AU752905B2 (en) | Electrically activated substance and method for making same | |
Omura | CRITICAL EVALUATION OF THE METHODS OF MEASUREMENT OF “TINGLING THRESHOLD | |
CA2291352A1 (en) | Method of providing cosmetic/medical therapy | |
JP2700242B2 (en) | Disease treatment equipment | |
WO1995029732A1 (en) | Multiple needle electrode | |
Massey | Practical electrotherapeutics and diathermy | |
CA2291559A1 (en) | Alternating current prepared medicament and uses thereof | |
MXPA01010024A (en) | Method of providing cosmetic/medical therapy | |
RU2066213C1 (en) | Biogalvanic massaging device | |
KR900005855B1 (en) | Stimulating apparatus for growth and revival of hair | |
SU1074542A1 (en) | Method of treatment of radiculitis | |
Elliott | Electro-therapeutics and X-rays | |
Redding | Aids to Electro-therapeutics | |
SU1161120A1 (en) | Method of treatment of rheumatoid arthritis | |
Braun III | A Journal For Physicians By Physicians | |
Intellectuelle | CANADIAN PATENT APPLICATION (13) A1 | |
Matijaca | Principles of Electro-medicine, Electro-surgery and Radiology: A Practical Treatise for Students and Practioners, with Chapters on Mechanical Vibration and Blood Pressure Technique | |
YOSHIDA et al. | Fundamental studies on electric stimulator used for acupuncture analgesia | |
Thom | Electrotherapy of paralyses | |
Waddington | Practical Index to Electro-physiotherapy: With Index of Diseases and Discriptive Techniques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 75886/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 500770 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998923647 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998923647 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 75886/98 Country of ref document: AU |